Form 4: Sonnet CMO's Stock Changes Post-HSI Merger
Insider Ownership Change
Sonnet BioTherapeutics Chief Medical Officer Richard T. Kenney reported significant changes in his beneficial ownership following the company's merger with Hyperliquid Strategies Inc.
Summary
- Sonnet BioTherapeutics Holdings, Inc. completed a business combination agreement (BCA) dated July 11, 2025, merging with Hyperliquid Strategies Inc (HSI), resulting in Sonnet becoming a direct wholly owned subsidiary of HSI.
- Chief Medical Officer Richard T. Kenney's 9,374 restricted stock units (including 8,000 vested due to the merger and 1,374 previously vested) were exchanged for one-fifth of a share of HSI Common Stock and one Contingent Value Right (CVR) per RSU.
- Warrants to purchase 86,505 shares of Sonnet Common Stock, issued on June 30, 2025, as partial consideration for a $200,000 convertible note, were automatically exercised on a cashless basis at the merger's effective time.
- In connection with the cashless exercise, 16,891 shares were withheld to pay the exercise price, based on a fair market value of $4.764 per share.
- These exercised warrants were then exchanged for one-fifth of a share of HSI Common Stock and one CVR.
- Warrants to purchase 320,000 shares of Sonnet Common Stock, issued on July 14, 2025, upon full conversion of the convertible note, were assumed by HSI and converted into warrants to acquire the same number of HSI Common Stock.
- 200 shares of Series 5 Preferred Stock, issued on July 14, 2025, convertible at $1.25 per share, were automatically converted into Sonnet Common Stock and then exchanged for one-fifth of a share of HSI Common Stock.
- All reported amounts reflect a 1:22 reverse stock split effective August 31, 2023, and a 1:8 reverse stock split effective September 30, 2024.
- Following these transactions, Richard T. Kenney's beneficial ownership of Sonnet BioTherapeutics Common Stock and derivative securities is 0.
Sentiment
Score: 5
Explanation: Neutral. The filing is a factual report of insider transactions following a merger. It's neither inherently positive nor negative for the company's operational performance, but rather a procedural update on ownership changes.
Positives
- The completion of the Business Combination Agreement signifies a strategic corporate event for Sonnet BioTherapeutics, integrating it into Hyperliquid Strategies Inc.
- Richard T. Kenney received shares of Hyperliquid Strategies Inc. Common Stock and Contingent Value Rights (CVRs) in exchange for his Sonnet equity, providing a new investment vehicle.
Negatives
- Richard T. Kenney's beneficial ownership of Sonnet BioTherapeutics Common Stock and derivative securities is now 0, indicating a complete exit from direct equity in Sonnet.
Future Outlook
This filing reports completed transactions related to a merger and does not provide explicit forward-looking statements or guidance from the company regarding future performance or strategy.
Industry Context
The merger of Sonnet BioTherapeutics into Hyperliquid Strategies Inc. reflects a strategic consolidation within the biotechnology or pharmaceutical sector, potentially aimed at leveraging synergies, expanding market reach, or streamlining operations under a larger entity.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Corporate Structure | Sonnet BioTherapeutics Holdings, Inc. merged into Company Merger Sub, with Sonnet surviving as a direct wholly owned subsidiary of Hyperliquid Strategies Inc (HSI). | 12/02/2025 | Significant change in corporate control and ownership structure, with Sonnet becoming a subsidiary of HSI, impacting its governance framework. |
Related Party Transactions
- Issuance of a $200,000 convertible note, warrants for 86,505 and 320,000 shares, and 200 shares of Series 5 Preferred Stock to Chief Medical Officer Richard T. Kenney prior to the merger.
Stakeholder Impact
- Shareholders of Sonnet BioTherapeutics Holdings, Inc. (including the reporting person) had their equity and derivative holdings converted into Hyperliquid Strategies Inc. Common Stock and Contingent Value Rights (CVRs) as a result of the merger.
- Management, specifically the Chief Medical Officer, has transitioned his equity exposure from Sonnet to the acquiring entity, HSI, and CVRs.
Key Dates
| Date | Description |
|---|---|
| 08/31/2023 | Effective date of Sonnet's 1:22 reverse stock split. |
| 09/30/2024 | Effective date of Sonnet's 1:8 reverse stock split. |
| 06/30/2025 | Reporting Person issued warrants to purchase 86,505 shares of Company Common Stock as partial consideration for a convertible note. |
| 07/11/2025 | Date of the Business Combination Agreement (BCA). 8,000 restricted stock units granted to Reporting Person. |
| 07/14/2025 | Reporting Person issued warrants to purchase 320,000 shares of Company Common Stock and 200 shares of Series 5 Preferred Stock upon conversion of the convertible note. |
| 12/02/2025 | Earliest Transaction Date; Effective Time of the Company Merger and related security conversions/exercises. |
| 12/04/2025 | Date Form 4 was filed. |
Keywords
Sonnet BioTherapeutics, SONN, Hyperliquid Strategies Inc, HSI, merger, acquisition, Form 4, insider trading, beneficial ownership, restricted stock units, warrants, preferred stock, CVR, Richard T. Kenney
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.